Colorectal Cancer Pipeline Analysis: 150+ Companies are working to improve the Treatment of Space

November 15 01:30 2022
Colorectal Cancer Pipeline Analysis: 150+ Companies are working to improve the Treatment of Space

DelveInsight’s, “Colorectal Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Colorectal Cancer Pipeline Report

  • DelveInsight’s colorectal cancer pipeline analysis depicts a robust space with 150+ active players working to develop 150+ pipeline therapies.
  • The leading Colorectal Cancer pipeline companies such as Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics,  Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.
  • Promising Colorectal cancer pipeline therapies in various stages of development include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811,  EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
  • This segment of the Colorectal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Colorectal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.

 

Recent Breakthroughs of Colorectal Cancer Treatment Landscape

  • In October 2022, Lyell Immunopharma announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845. Phase I trial to initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer.
  • In September 2022, Agenus announced the initiation of a global Phase II program of botensilimab, an Fc-enhanced anti-CTLA-4 that activates innate and adaptive immune responses. These trials include ACTIVATE-Colorectal, a Phase II study designed to evaluate botensilimab as monotherapy and in combination with balstilimab (anti-PD-1) for the treatment of microsatellite stable colorectal cancer.
  • In September 2022, BioNTech announced that the first colorectal cancer patient had been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase II clinical trial.
  • In August 2022, ALX Oncology initiated the Phase II clinical trial of evorpacept plus Erbitux (cetuximab) and Keytruda (pembrolizumab) in refractory microsatellite stable metastatic colorectal cancer (mCRC) patients. The combination treatment is intended for mCRC patients who have advanced following a minimum of two lines of systemic therapy.
  • In August 2022, Celyad Oncology announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria for the trial.
  • In June 2022, Exelixis announced the initiation of STELLAR-303, a Phase III pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy.

 

Request a sample and discover the recent advances in Colorectal Cancer treatment @ Colorectal Cancer Pipeline Report

 

Colorectal Cancer Overview

Colorectal cancer refers to cancer in the colon and/or rectum, or both. As the graphic below shows, the colon is part of the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Most colorectal cancers develop first as polyps, which are abnormal growths inside the colon or rectum that may later become cancerous if they are not removed. Colorectal cancer (cancer of the colon or rectum) is very treatable when it is discovered early. Even if it spreads into nearby lymph nodes, surgical treatment followed by chemotherapy is very effective. In the most advanced cases — when the cancer has spread to the liver, lungs, or other sites — treatment can often make surgery an option, and can prolong and add to quality of life. Research is constantly being done to learn more and provide hope for people in all colorectal cancer stages.

 

Colorectal Cancer Emerging Drugs 

Patritumab Deruxtecan: Daiichi Sankyo Company

Patritumab deruxtecan (HER3-DXd, U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a human anti-HER3 antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. 

Adagrasib: Mirati Therapeutics

Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. Currently, the drug is in Phase III stage of clinical trial evaluation to treat colorectal cancer. 

Etrumadenant: Arcus Biosciences

Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS- mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects. 

AL2846: Advenchen Laboratories

AL2846 is a c-Met receptor tyrosine kinase (RTK) inhibitor and it also inhibits other RTKs of Flt4, KDR, Axl and Ron being developed by Advenchen Laboratories. Currently, the drug is in Phase I/II stage of clinical trial evaluation to treat colorectal cancer. 

Onvansertib: Cardiff Oncology

Onvansertib is a First-In-Class, Third-Generation, Oral and Highly-Selective PLK1 Inhibitor. The drug is in phase 1/2 of clinical trials for the treatment of patients with colorectal cancer.

 

Colorectal Cancer Pipeline Therapeutic Assessment

There are approx. 150+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

 

DelveInsight’s Colorectal Cancer Pipeline report covers around 150+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Learn more about the emerging colorectal cancer pipeline therapies @ Colorectal Cancer Clinical Trials

 

Scope of the Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Colorectal Cancer Pipeline Assessment by Product Type
  • Colorectal Cancer Pipeline Assessment by Stage and Product Type
  • Colorectal Cancer Pipeline Assessment by Route of Administration
  • Colorectal Cancer Pipeline Assessment by Stage and Route of Administration
  • Colorectal Cancer Pipeline Assessment by Molecule Type
  • Colorectal Cancer Pipeline Assessment by Stage and Molecule Type
  • Colorectal Cancer Pipeline Companies- Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics,  Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.
  • Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811,  EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Colorectal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Colorectal Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Adagrasib: Mirati Therapeutics
  9. Mid Stage Products (Phase II)
  10. Patritumab Deruxtecan: Daiichi Sankyo Company
  11. Early Stage Products (Phase I)
  12. BI 905711: Boehringer Ingelheim
  13. Preclinical and Discovery Stage Products
  14. AM 401: Altamira Therapeutics
  15. Inactive Products
  16. Colorectal Cancer Key Companies
  17. Colorectal Cancer Key Products
  18. Colorectal Cancer- Unmet Needs
  19. Colorectal Cancer- Market Drivers and Barriers
  20. Colorectal Cancer- Future Perspectives and Conclusion
  21. Colorectal Cancer Analyst Views
  22. Colorectal Cancer Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Colorectal Cancer drugs?
  • How many Colorectal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Colorectal Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Colorectal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Colorectal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Colorectal Cancer Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/